Back
  1. Home
  3. Detailed Reference
Download
Paper published in a journal (Scientific congresses and symposiums)
1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
Monk, B.J.; Van Nieuwenhuysen, E.; Tromp, J. et al.
2025 • In Annals of Oncology, 36, p. 769-S770
Editorial reviewed
Permalink
https://hdl.handle.net/2268/337549
DOI
10.1016/j.annonc.2025.08.1802
 

Files (1)Send toDetailsStatisticsBibliographySimilar publications

Files

Full Text
1166P Tisotumab.pdf
Publisher postprint (243.84 kB)
Download

All documents in ORBi are protected by a user license.

Send to


Details


Disciplines :
Oncology
Author, co-author :
Monk, B.J.
Van Nieuwenhuysen, E.
Tromp, J.
Lorusso, D.
O'Cearbhaill, R.E.
Banerjee, S.
Collins, D.C.
Zikan, M.
Jackson, A.L.
Madsen, K.
Gennigens, Christine  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Ottevanger, P.B.
Ghamande, S.
Salutari, V.
Baurain, J-F.
Reyners, A.
Conte, U.
Windfeld, K.
Hansen, H.
Vergote, I.
More authors (10 more) Less
Language :
English
Title :
1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
Publication date :
September 2025
Event name :
ESMO Congress 2025
Event place :
Berlin, Germany
Event date :
17-21 October 2025
Audience :
International
Journal title :
Annals of Oncology
ISSN :
0923-7534
eISSN :
1569-8041
Publisher :
Elsevier
Volume :
36
Pages :
S769-S770
Peer review/Selection committee :
Editorial reviewed
Additional URL :
https://api.elsevier.com/content/article/PII:S092375342502722X?httpAccept=text/xml
Funders :
Pfizer
Available on ORBi :
since 14 November 2025

Statistics

Number of views
18 (0 by ULiège)
Number of downloads
2 (0 by ULiège)
More statistics
OpenCitations
 
0
OpenAlex citations
 
0

Bibliography

Similar publications


Contact ORBi